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Very early MRI responses to therapy as a
predictor of later radiographic progression
in early rheumatoid arthritis
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Bethanie Wilkinson5, Zhiyong Xie5, John Andrews6, Amy Stein7, Douglass Chapman6 and Andrew Koenig8
Abstract
Background: The objective of this study was to evaluate early changes in magnetic resonance imaging (MRI) and
clinical disease activity measures as predictors of later structural progression in early rheumatoid arthritis (RA).
Methods: This was a post hoc analysis of data pooled across treatments from a three-arm (tofacitinib monotherapy,
tofacitinib with methotrexate [MTX], or MTX monotherapy) trial of MTX-naïve patients with early, active RA.
Synovitis, osteitis and erosions were assessed with the Outcome Measures in Rheumatology (OMERACT) RA MRI
scoring system (RAMRIS) and RAMRIQ (automated quantitative RA MRI assessment system; automated RAMRIS) at
months 0, 1, 3, 6 and 12. Radiographs were assessed at months 0, 6 and 12, and clinical endpoints were assessed at
all timepoints. Univariate and multivariate analyses explored the predictive value of early changes in RAMRIS/
RAMRIQ parameters and disease activity measures, with respect to subsequent radiographic progression.
Results: Data from 109 patients with a mean RA duration of 0.7 years were included. In univariate analyses, changes
in RAMRIS erosions at months 1 and 3 significantly predicted radiographic progression at month 12 (both p < 0.01);
changes in RAMRIQ synovitis and osteitis at months 1 and 3 were significant predictors of RAMRIS erosions and
radiographic progression at month 12 (all p < 0.01). In subsequent multivariate analyses, RAMRIS erosion change at
month 1 (p < 0.05) and RAMRIQ osteitis changes at months 1 and 3 (both p < 0.01) were significant independent
predictors of radiographic progression at month 12. Univariate analyses demonstrated that changes in Clinical
Disease Activity Index (CDAI) and Disease Activity Score in 28 joints, erythrocyte sedimentation rate (DAS28-4[ESR])
at months 1 and 3 were not predictive of month 12 radiographic progression.
Conclusions: MRI changes seen as early as 1 month after RA treatment initiation have the potential to better
predict long-term radiographic progression than changes in disease activity measures.
Trial registration: ClinicalTrials.gov, NCT01164579.
Keywords: Bone erosion, Disease activity, Joint space narrowing, Osteitis, Predictive ability, Radiographic
progression, RAMRIS, RAMRIQ, Rheumatoid arthritis, Synovitis
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Background
Rheumatoid arthritis (RA) has a substantial impact on
patients, with joint inflammation resulting in pain and
destruction of the joints, leading to reduced quality of
life and substantial disability [1]. A treat-to-target ap-
proach is recommended in RA, with regular assessments
and adjustment of treatment for inadequate response [2,
3]. Studies have demonstrated clinical response to
therapy at months 1 to 3 to be predictive of longer-term
achievement of clinical targets (decrease in Disease
Activity Score in 28 joints, erythrocyte sedimentation
rate [DAS28-4(ESR)] and Clinical Disease Activity Index
[CDAI]) with conventional synthetic disease-modifying
antirheumatic drugs (DMARDs) [4], biologic DMARDs
[5] and the Janus kinase (JAK) inhibitor, baricitinib [6].
Magnetic resonance imaging (MRI) can assess
inflammation (synovitis and bone marrow edema/osteitis)
as well as damage (erosions) in joints, using the semi-
quantitative Outcome Measures in Rheumatology
(OMERACT) RA MRI scoring system (RAMRIS) [7, 8]
and, more recently, the automated quantitative RA MRI
assessment system (RAMRIQ; automated RAMRIS) [8, 9].
This sensitivity for pathology detection may provide a tool
for accurate early detection of an objective treatment
response.
Tofacitinib is an oral JAK inhibitor for the treatment of
RA. In a phase 2 study of tofacitinib 10mg twice daily
(BID) with and without concomitant methotrexate
(MTX), tofacitinib reduced inflammation and inhibited
progression of structural damage from baseline to
month 12 compared with treatment with MTX alone,
as assessed using RAMRIS and RAMRIQ [8].
The aim of this post hoc analysis was therefore to
evaluate early changes in MRI and clinical measures in
this phase 2 study as predictors of later structural changes.
Methods
Study design and patients
This was a post hoc analysis of data from a 1-year,
exploratory, phase 2, randomised, double-blind, parallel-
group study (A3921068; NCT01164579). Full details of
the study design and patient population have been re-
ported previously [8]. Briefly, patients aged ≥ 18 years with
active RA were randomised 1:1:1 to tofacitinib 10mg BID
monotherapy, tofacitinib 10mg BID with MTX, or MTX
monotherapy. Patients had RA of ≤ 2 years’ duration and
103/109 (94%) patients were MTX-naïve. This study was
approved by the Institutional Review Boards and/or
Independent Ethics Committees at each investigational
centre, and all patients provided written informed consent.
MRI and radiography
MRIs of unilateral wrist and metacarpophalangeal (MCP)
joints were obtained at screening and months 1, 3, 6 and 12,
and were used to assess synovitis, osteitis (bone marrow
oedema) and erosions using RAMRIS [7] and RAMRIQ
[9]. The hand that was most clinically affected at screening
was chosen for MRI assessment throughout the study. If
both hands were equally affected, the dominant hand was
chosen. Radiographic progression was based on mean
change from baseline in modified Total Sharp Scores
(mTSS) [10], determined from radiographs at baseline,
month 6 and month 12. The OMERACT RAMRIS semi-
quantitatively assessed osteitis (using short-tau inversion
recovery sequences), synovitis (using pre/post-contrast
T1-weighted sequences) and bone erosions (using
T1-weighted sequences) in three areas of the wrist
and in MCP joints 1–5 [7], using a single, centralised
reader, blinded to chronology and all clinical and im-
aging data. RAMRIQ is a fully automated quantitative
measurement system (Imorphics, Manchester, UK) that
assessed the same three pathologies as RAMRIS. For
RAMRIQ assessments, the pre-contrast and post-contrast
T1-weighted MRI sequences of the same joints and bones
were used. The system is based on the accurate 3D
segmentation of finger bones using a method based on
statistical shape models that identify the whole bone in 3D
and are therefore less susceptible to differences between
readers and hand position in the MRI coil. Synovitis vol-
ume is the volume of the regions around the joint where
the synovial capsule is found that enhances with contrast
agent on T1-weighted images. Osteitis volume is the vol-
ume inside the bone that enhances with contrast agent on
T1-weighted images. Finally, erosions are measured as the
volume of bone (either the complete bone, or the bone
within 15mm of the joint [10mm for RAMRIS] for longer
bones) that is classified as ‘not healthy’ using a machine-
vision classification method. RAMRIQ osteitis values were
reported as normalised volume (%) calculated as (total
volume osteitis/total bone volume) × 100, and RAMRIQ
erosions values were also reported as normalised volume
(%), calculated as (total volume eroded bone/total bone
volume) × 100.
Disease activity
Disease activity endpoints were changes from baseline at
months 1 and 3 in CDAI scores and DAS28-4(ESR).
Statistical methods and analysis
Analyses were on data pooled across treatment groups,
given the sample size. Pooled analyses were performed, as
reliable markers of RA progression should not differ in
their predictive value across treatment groups; thus,
pooled analyses allow for more generalisation.
Univariate linear regression analyses were used to assess
the predictive value of changes in RAMRIS synovitis,
osteitis and erosions from baseline to month 1 and,
separately, from baseline to month 3, with respect to
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radiographic progression (mTSS) from baseline to month 12.
Additionally, univariate linear regression analyses were used
to assess the predictive value of changes in RAMRIQ
synovitis, osteitis and erosions from baseline to month 1
and, separately, from baseline to month 3, with respect to
changes in RAMRIS erosions and radiographic progression
between baseline and month 12. Based on the results of the
univariate analyses, we performed subsequent multivariate
linear regression analyses of changes from baseline to
month 1 and, separately, from baseline to month 3, with
respect to radiographic progression from baseline to
month 12, which included the RAMRIS and RAMRIQ
variables that were shown to be statistically significant
predictors in the univariate analyses. Univariate analyses
were also used to assess the predictive value of changes in
CDAI and DAS28-4(ESR) from baseline to month 1 and,
separately, from baseline to month 3, with respect to
radiographic progression from baseline to month 12.
Statistical significance was considered to have been
demonstrated with p values < 0.05; multiplicity was not
adjusted for.
Results
Patients
Overall, 109 patients, 103 of whom were MTX-naïve, with
mean ± standard deviation duration of RA of 0.7 ± 1.0
years were randomised, 36 to each tofacitinib 10mg BID
group (±MTX) and 37 to MTX monotherapy. Patient
demographics and baseline disease characteristics have
been reported previously and were generally well-balanced
between treatment groups [8].
Radiographic progression
mTSS at baseline, month 6 and month 12, and least
squares mean changes from baseline in mTSS at month 6
and month 12, are reported in Additional file 1.
Early RAMRIS changes as predictors of radiographic
progression and joint space narrowing (JSN)
In univariate analyses, lower increases from baseline to
both months 1 and 3 in RAMRIS erosions were significant
predictors of less radiographic progression from baseline
to month 12. Furthermore, lower increases from baseline
to both months 1 and 3 in RAMRIS erosions significantly
predicted less radiographic erosion from baseline to
month 12, and lower increases from baseline to month 1
in RAMRIS erosions significantly predicted less JSN from
baseline to month 12. No significant predictive value was
observed between change from baseline to month 1 or 3
in RAMRIS synovitis or osteitis or between baseline and
month 12 in radiographic progression, radiographic
erosions, or JSN (Table 1).
Early RAMRIQ changes as predictors of RAMRIS erosion
progression and radiographic progression
n univariate analyses, lower increases from baseline to
both months 1 and 3 in RAMRIQ synovitis and osteitis
were significant predictors of smaller changes in RAMRIS
erosions from baseline to month 12. Lower changes from
baseline to both months 1 and 3 in RAMRIQ synovitis
and osteitis (but not RAMRIQ erosions) also signifi-
cantly predicted less total radiographic progression
(change in mTSS) and JSN progression between
baseline and month 12 (Table 1).
Early changes in RAMRIS erosions and RAMRIQ synovitis
and osteitis as predictors of radiographic progression
Baseline variables, including age, gender, race and
smoking status, were not significant in univariate analyses
(data not shown) and therefore were not included in the
subsequent multivariate analyses. In multivariate analyses,
the change in RAMRIS erosions from baseline to month 1,
but not from baseline to month 3, was a significant
independent predictor of total radiographic progression
from baseline to month 12, and the changes in RAMRIS
erosions from baseline to both months 1 and 3 were
significant independent predictors of radiographic erosion
progression from baseline to month 12 (Table 2). Further-
more, changes in RAMRIQ osteitis (but not RAMRIQ
synovitis) at both months 1 and 3 were significant
independent predictors of total and JSN radiographic
progression from baseline to month 12, and the change in
RAMRIQ synovitis at month 1, but not at month 3, was a
significant independent predictor of radiographic erosion
progression from baseline to month 12 (Table 2).
Early changes in disease activity as predictors of
radiographic progression
In univariate analyses, there was no significant predictive
value (p values > 0.05 for all analyses) of changes from
baseline to month 1 or 3 in CDAI or DAS28-4(ESR)
with respect to radiographic progression from baseline
to month 12 (Additional file 2).
Discussion
Data from an RA clinical trial with a small number of
patients, pooled across treatment groups, demonstrated
that MRI assessment at months 1 and 3 after treatment
initiation, using RAMRIS or the automated system
RAMRIQ, generally predicted radiographic disease
progression from baseline to month 12. Of the changes
assessed, changes as early as month 1 in RAMRIQ
synovitis and osteitis and in RAMRIS erosions were the
best predictors of later disease progression. No predictive
value was observed for concomitant changes from baseline
to months 1 and 3 in the CDAI and DAS28-4(ESR) dis-
ease activity measures and later radiographic progression.
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A number of studies have looked at baseline MRI
features predicting outcome. An observational study of
patients with RA of < 1 year’s duration reported that
RAMRIS-assessed osteitis at baseline was associated with
radiographic progression at 1 year [11], and in a rando-
mised controlled trial in patients with early RA, baseline
osteitis assessed with RAMRIS was a strong predictor of
radiographic progression after 2 years [12]. In terms of
response prediction, in a clinical trial of golimumab in
MTX-naïve patients with RA, multivariate logistic
regression analysis of RAMRIS-assessed changes showed
synovitis and osteitis at baseline and after 24 weeks of treat-
ment predicted radiographic progression at 12months, as
did an increase in erosion of > 0.5 at weeks 12 and 24; re-
gression models incorporating baseline and 12- and
24-week changes in MRI measures of synovitis and osteitis
improved the prediction of radiographic progression at
12months above clinical disease activity measures [13].
However, we believe this to be the first report of
MRI-detected changes as early as 1 month predicting
radiographic progression after 12 months.
Given that it has been demonstrated that there is a
window of opportunity in RA, an early predictor of disease
progression at month 12 could allow treatment decisions to
be made sooner, in line with the recommended treat-to-
target approach in RA [2, 3]. The most effective early
RA intervention will ideally lead to reduced long-term
impact of the disease; thus, early identification of the
likely long-term efficacy of treatment provides potential
patient benefit [14]. Early prediction of longer-term
Table 1 Univariate analysesa of predictive value of early MRI changes for later MRI and radiographic changes
Change from baseline to month 1 Change from baseline to month 3
Change from baseline to
month 12
RAMRIS
synovitis
RAMRIS
osteitis
RAMRIS
erosions
RAMRIS
synovitis
RAMRIS
osteitis
RAMRIS
erosions
Total radiographic
progressionb
Estimate (SE);
p value
0.044 (0.241);
0.856
0.007 (0.175);
0.971
1.431 (0.408);
< 0.001
0.101 (0.188);
0.592
− 0.087 (0.138);
0.533
0.748 (0.252);
0.004
Radiographic erosion
progression
Estimate (SE);
p value
0.039 (0.118);
0.743
0.031 (0.085);
0.718
0.638 (0.201);
0.002
0.087 (0.091);
0.339
− 0.013 (0.067);
0.853
0.455 (0.118);
< 0.001
Radiographic JSN
progression
Estimate (SE);
p value
0.010 (0.163);
0.951
− 0.024 (0.118);
0.837
0.792 (0.284);
0.007
0.015 (0.127);
0.905
− 0.074 (0.093);
0.434
0.295 (0.179);
0.104
RAMRIQ
synovitisc
RAMRIQ
osteitis
RAMRIQ
erosions
RAMRIQ
synovitisc
RAMRIQ
osteitis
RAMRIQ
erosions
RAMRIS erosion
progression
Estimate (SE);
p value
0.0002 (0.0001);
0.004
0.287 (0.085);
0.001
– 0.0001 (0.0000);
0.008
0.354 (0.089);
< 0.001
–
Total radiographic
progression b
Estimate (SE);
p value
0.0004 (0.0001);
< 0.001
0.930 (0.154);
< 0.001
1.552 (0.846);
0.072
0.0002 (0.0001);
0.008
1.099 (0.222);
< 0.001
− 0.498 (0.786);
0.529
Radiographic erosion
progression
Estimate (SE);
p value
0.0001 (0.0000);
0.011
0.182 (0.092);
0.052
0.531 (0.417);
0.208
0.0001 (0.0000);
0.048
0.220 (0.123);
0.080
− 0.231 (0.382);
0.548
Radiographic JSN
progression
Estimate (SE);
p value
0.0003 (0.0001);
< 0.001
0.748 (0.089);
< 0.001
1.017 (0.572);
0.080
0.0002 (0.0001);
0.012
0.879 (0.138);
< 0.001
− 0.269 (0.533);
0.615
aBased on univariate linear regression analysis
bAssessed by mTSS
cRAMRIQ synovitis is not normalised, where RAMRIQ osteitis and erosions are; as a result, the estimates and standard errors are low due to the scale
JSN joint space narrowing, MRI magnetic resonance imaging, mTSS modified Total Sharp Score, RA rheumatoid arthritis, RAMRIQ automated quantitative RA MRI
assessment system, RAMRIS RA MRI scoring system, SE standard error
Table 2 Multivariate analysesa of predictive value of early MRI changes for later radiographic changes
Change from baseline to month 1 Change from baseline to month 3
Change from baseline to month 12 RAMRIQ
synovitis
RAMRIQ
osteitis
RAMRIS
erosions
RAMRIQ
synovitis
RAMRIQ
osteitis
RAMRIS
erosions
Total radiographic progressionb Estimate 0.0002 0.645 0.777 0.0001 0.867 0.434
p value 0.148 0.002 0.043 0.407 0.001 0.073
Radiographic erosion progression Estimate 0.0001 − 0.043 0.590 0.0001 − 0.001 0.425
p value 0.040 0.705 0.007 0.145 0.996 0.001
Radiographic JSN progression Estimate 0.0000 0.688 0.187 0.0000 0.868 0.009
p value 0.647 < 0.001 0.409 0.907 < 0.001 0.954
aBased on multivariate linear regression analysis
bAssessed by mTSS
JSN joint space narrowing, MRI magnetic resonance imaging, mTSS modified Total Sharp Score, RA rheumatoid arthritis, RAMRIQ automated quantitative RA MRI
assessment system, RAMRIS RA MRI scoring system
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structural treatment benefit might also allow clinical trials
of shorter duration and with more limited sample size,
focused on structural changes, to be designed to assess
new agents for the treatment of RA. Such trials would be
preferable from the patient perspective and could also
reduce drug development costs by rapidly assessing the
clinical response to new therapies and reducing the need
for additional imaging studies.
Early changes in disease activity, as measured with CDAI
and DAS28-4(ESR), showed no significant predictive value
for subsequent structural damage progression. Thus, the
analyses presented here demonstrated that MRI assessment
of structural changes during the first 3months of treatment
for RA, and even as early as 1month, may better predict
patients’ radiographically assessed response to treatment by
month 12 than changes in clinical measures of disease
activity in those 3months. The MRI scoring procedures
included here can be implemented using widely available
MRI equipment (1.5-T scanners) and imaging sequences,
as described previously [8].
A number of limitations of this study are acknowledged.
The small sample size, post hoc nature of the analysis,
single RAMRIS reader and lack of independence of the
predictive parameters assessed all indicate a need for cau-
tion in the interpretation of findings. These analyses were
exploratory in nature with the intent to determine which
parameters had the strongest ability to predict treatment
response. While this analysis, based on clinical trial data,
demonstrated the utility of the RAMRIQ technique, the
technology is still under development. Implementation in
non-clinical-trial settings may be subject to variability due
to potential variability in the implementation of the
RAMRIS/RAMRIQ protocol across different magnetic
field strengths, and possible inter-operator differences.
Further exploration of this finding with other agents is
warranted to evaluate the clinical implications.
Conclusions
In conclusion, incorporation of early MRI measurement in
RA clinical trials will likely enable prediction of later
response to treatment, allowing more rapid assessment of
the efficacy of new medications. There is also the potential
to use MRI as a biomarker to inform treatment decisions in
clinical practice. However, the findings reported here
require further validation.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13075-019-2000-1.
Additional file 1: Descriptive statistics of mTSS and statistical analysis of
change from baseline in mTSS over time.
Additional file 2: Univariate analysesa of predictive value of early
changes in CDAI and DAS28-4(ESR) for later radiographic changes.
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